AC Immune (NASDAQ:ACIU – Get Free Report) has been given an average rating of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $7.50.
ACIU has been the topic of several research reports. HC Wainwright reaffirmed a “buy” rating on shares of AC Immune in a research report on Thursday, September 24th. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research report on Wednesday, September 23rd. Zacks Research upgraded AC Immune from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 29th. Finally, Weiss Ratings cut AC Immune from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 20th.
View Our Latest Stock Analysis on ACIU
AC Immune Stock Performance
Shares of ACIU opened at $2.42 on Monday. The firm’s 50-day moving average price is $2.65 and its 200-day moving average price is $2.62. The firm has a market capitalization of $246.28 million, a price-to-earnings ratio of -4.48 and a beta of 1.56. AC Immune has a 1-year low of $2.10 and a 1-year high of $4.00.
AC Immune (NASDAQ:ACIU – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.13. AC Immune had a negative net margin of 245.32% and a negative return on equity of 100.17%. The company had revenue of $18.67 million for the quarter, compared to analysts’ expectations of $9.59 million. On average, research analysts forecast that AC Immune will post -0.60 EPS for the current fiscal year.
Hedge Funds Weigh In On AC Immune
Institutional investors have recently added to or reduced their stakes in the company. AXQ Capital LP purchased a new stake in AC Immune during the 2nd quarter valued at about $25,000. Arrowstreet Capital Limited Partnership increased its stake in AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock valued at $1,116,000 after purchasing an additional 30,035 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AC Immune by 82.8% in the first quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.
AC Immune Company Profile
AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.
The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.
Featured Stories
- Five stocks we like better than AC Immune
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.
